BMND15
MCID: BNM029
MIFTS: 48

Bone Mineral Density Quantitative Trait Locus 15 (BMND15)

Categories: Bone diseases, Fetal diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Bone Mineral Density Quantitative Trait Locus 15

MalaCards integrated aliases for Bone Mineral Density Quantitative Trait Locus 15:

Name: Bone Mineral Density Quantitative Trait Locus 15 56 6 39
Osteoporosis 56 71
Metaphyseal Fracture, Susceptibility to 56
Compression Fracture, Susceptibility to 56
Osteoporosis, Susceptibility to 56
Fractures, Compression 71
Metaphyseal Fractures 6
Metaphyseal Fracture 56
Compression Fracture 56
Bmnd15 56

Characteristics:

OMIM:

56
Inheritance:
autosomal recessive
autosomal dominant


HPO:

31
bone mineral density quantitative trait locus 15:
Inheritance autosomal dominant inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 56 613418
MedGen 41 C3150680
SNOMED-CT via HPO 68 258211005 263681008 64859006
UMLS 71 C0029456 C0521169

Summaries for Bone Mineral Density Quantitative Trait Locus 15

MalaCards based summary : Bone Mineral Density Quantitative Trait Locus 15, also known as osteoporosis, is related to osteoporosis and osteoporosis, juvenile, and has symptoms including tremor, back pain and angina pectoris. An important gene associated with Bone Mineral Density Quantitative Trait Locus 15 is MIR2861 (MicroRNA 2861). The drugs Linagliptin and Dinoprostone have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and prostate, and related phenotype is osteoporosis.

More information from OMIM: 613418

Related Diseases for Bone Mineral Density Quantitative Trait Locus 15

Diseases in the Bone Mineral Density Quantitative Trait Locus 15 family:

Bone Mineral Density Quantitative Trait Locus 4 Bone Mineral Density Quantitative Trait Locus 18
Bone Mineral Density Quantitative Trait Locus 1 Bone Mineral Density Quantitative Trait Locus 2
Bone Mineral Density Quantitative Trait Locus 3 Bone Mineral Density Quantitative Trait Locus 5
Bone Mineral Density Quantitative Trait Locus 6 Bone Mineral Density Quantitative Trait Locus 7
Bone Mineral Density Quantitative Trait Locus 8 Bone Mineral Density Quantitative Trait Locus 9
Bone Mineral Density Quantitative Trait Locus 10 Bone Mineral Density Quantitative Trait Locus 11
Bone Mineral Density Quantitative Trait Locus 12 Bone Mineral Density Quantitative Trait Locus 13
Bone Mineral Density Quantitative Trait Locus 14 Bone Mineral Density Quantitative Trait Locus 16
Bone Mineral Density Quantitative Trait Locus 17

Diseases related to Bone Mineral Density Quantitative Trait Locus 15 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1098)
# Related Disease Score Top Affiliating Genes
1 osteoporosis 33.2 PDLIM4 MIR2861 CALCR
2 osteoporosis, juvenile 12.9
3 osteoporosis-pseudoglioma syndrome 12.8
4 nephrolithiasis/osteoporosis, hypophosphatemic, 1 12.7
5 glucocorticoid-induced osteoporosis 12.6
6 juvenile primary osteoporosis 12.6
7 nephrolithiasis/osteoporosis, hypophosphatemic, 2 12.6
8 osteoporosis and oculocutaneous hypopigmentation syndrome 12.5
9 hypophosphatemic nephrolithiasis/osteoporosis 12.4
10 macroepiphyseal dysplasia with osteoporosis, wrinkled skin, and aged appearance 12.3
11 hajdu-cheney syndrome 12.3
12 growth failure, microcephaly, mental retardation, cataracts, large joint contractures, osteoporosis, cortical dysplasia, and cerebellar atrophy 12.2
13 dominant hypophosphatemia with nephrolithiasis or osteoporosis 12.2
14 bone mineral density quantitative trait locus 8 12.2
15 amino aciduria with mental deficiency, dwarfism, muscular dystrophy, osteoporosis, and acidosis 12.2
16 cutis laxa osteoporosis 12.1
17 osteoporosis-macrocephaly-blindness-joint hyperlaxity syndrome 12.1
18 lrp5-related primary osteoporosis 12.1
19 bone mineral density quantitative trait locus 18 12.0
20 bone mineral density quantitative trait locus 16 11.8
21 premature ovarian failure 1 11.7
22 werner syndrome 11.6
23 aromatase deficiency 11.6
24 bone disease 11.6
25 bone mineral density quantitative trait locus 12 11.6
26 rickets 11.6
27 syndromic x-linked intellectual disability snyder type 11.6
28 lysinuric protein intolerance 11.5
29 mental retardation, x-linked, syndromic, snyder-robinson type 11.5
30 geroderma osteodysplasticum 11.5
31 hyperparathyroidism 11.5
32 hypogonadotropic hypogonadism 11.5
33 premature aging syndrome, okamoto type 11.4
34 cerebrotendinous xanthomatosis 11.4
35 acth-secreting pituitary adenoma 11.4
36 cholangitis, primary sclerosing 11.4
37 spondyloocular syndrome 11.4
38 cleidocranial dysplasia 11.4
39 hyperthyroidism 11.4
40 anorexia nervosa 11.4
41 celiac disease 1 11.4
42 systemic mastocytosis 11.4
43 spondyloepimetaphyseal dysplasia, shohat type 11.3
44 eating disorder 11.3
45 osteopetrosis 11.3
46 multicentric osteolysis, nodulosis, and arthropathy 11.3
47 graves' disease 11.3
48 turner syndrome 11.3
49 severe congenital neutropenia 11.3
50 pituitary adenoma 4, acth-secreting 11.3

Graphical network of the top 20 diseases related to Bone Mineral Density Quantitative Trait Locus 15:



Diseases related to Bone Mineral Density Quantitative Trait Locus 15

Symptoms & Phenotypes for Bone Mineral Density Quantitative Trait Locus 15

Human phenotypes related to Bone Mineral Density Quantitative Trait Locus 15:

31
# Description HPO Frequency HPO Source Accession
1 osteoporosis 31 HP:0000939

Symptoms via clinical synopsis from OMIM:

56
Skeletal:
osteoporosis
compression fractures (in homozygotes)
metaphyseal fractures (in homozygotes)

Clinical features from OMIM:

613418

UMLS symptoms related to Bone Mineral Density Quantitative Trait Locus 15:


tremor, back pain, angina pectoris, sciatica, equilibration disorder, muscle cramp, pelvic pain

Drugs & Therapeutics for Bone Mineral Density Quantitative Trait Locus 15

Drugs for Bone Mineral Density Quantitative Trait Locus 15 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 606)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Linagliptin Approved Phase 4 668270-12-0 10096344
2
Dinoprostone Approved Phase 4 363-24-6 5280360
3
Acetaminophen Approved Phase 4 103-90-2 1983
4
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
5
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
6
Teriparatide Approved, Investigational Phase 4 52232-67-4 16133850
7
Risedronate Approved, Investigational Phase 4 105462-24-6 5245
8
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
9
Tibolone Approved, Investigational Phase 4 5630-53-5
10
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
11
Atorvastatin Approved Phase 4 134523-00-5 60823
12
Etanercept Approved, Investigational Phase 4 185243-69-0
13
Pamidronate Approved Phase 4 40391-99-9 4674
14
Adalimumab Approved Phase 4 331731-18-1 16219006
15
Montelukast Approved Phase 4 158966-92-8 5281040
16
Lactitol Approved, Investigational Phase 4 585-88-6, 585-86-4 493591
17
Potassium citrate Approved, Investigational, Vet_approved Phase 4 866-84-2
18
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
19
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
20
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
21
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
22
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
23
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
24
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
25
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
26
Gliclazide Approved Phase 4 21187-98-4 3475
27
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
28
Basiliximab Approved, Investigational Phase 4 152923-56-3, 179045-86-4
29
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
30
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
31
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
32
Ribavirin Approved Phase 4 36791-04-5 37542
33
Liraglutide Approved Phase 4 204656-20-2 44147092
34
Azathioprine Approved Phase 4 446-86-6 2265
35
Darunavir Approved Phase 4 206361-99-1, 635728-49-3 213039
36
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
37
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
38
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
39
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
40
Morphine Approved, Investigational Phase 4 57-27-2 5288826
41
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
42
Salmon calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
43
Calcium carbonate Approved, Investigational Phase 4 471-34-1
44
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
45
Sodium citrate Approved, Investigational Phase 4 68-04-2
46
Bicalutamide Approved Phase 4 90357-06-5 2375 56069
47
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
48
Goserelin Approved Phase 4 65807-02-5 5311128 47725
49
Cinacalcet Approved Phase 4 226256-56-0 156419
50
Flutamide Approved, Investigational Phase 4 13311-84-7 3397

Interventional clinical trials:

(show top 50) (show all 2231)
# Name Status NCT ID Phase Drugs
1 Pilot Study: Does Preventive Adjacent Level Cement Augmentation Positively Affect Reoperation Rates After Osteoporotic Vertebral Compression Fractures? Unknown status NCT02489825 Phase 4
2 Comparación de la Eficacia y Seguridad clínicas de Osteofortil Respecto de Forteo Unknown status NCT01945788 Phase 4 Teriparatide (rDNA origin)
3 Evaluation of the Influence of Alendronate on Wound Healing After Dental Implants in Patients With Osteoporosis Unknown status NCT00727493 Phase 4 alendronate once weekly 70mg;placebo
4 Effect of Mechanical Loading With PTH on Cortical Bone Unknown status NCT03232476 Phase 4
5 Comparisons of the Effect of Inactive and Active Vitamin D on Serum Sclerostin/dickkopf1 Levels Unknown status NCT01765010 Phase 4 Calcitriol;Alfacalcidol;Cholecalciferol;Placebo
6 Generic Zoledronic Acid Versus Original Zoledronic Acid: A Multicenter, Randomized, Open, Paralled-controlled Clinical Postmenopausal Osteoporotic Women Efficacy and Safety Research. Unknown status NCT03158246 Phase 4 Generic Zoledronic Acid;Original Zoledronic Acid
7 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
8 Changes of Bone Metabolic Markers and Bone Mineral Density After Denosumab and/or Teriparatide Treatment in Japanese Osteoporotic Patients Unknown status NCT02156960 Phase 4 Denosumab treatment in osteoporotic patients;Teriparatide treatment in osteoporotic patients;Denosumab and teriparatide treatment in osteoporotic patients
9 Pharmacodynamics Study to Investigate the Effect of Evogliptin on Bone Metabolism in Healthy Volunteers Unknown status NCT02587975 Phase 4 Evogliptin
10 Randomized Trial Comparing Efficacy and Safety of Brand Versus Generic Alendronate for Osteoporosis Treatment Unknown status NCT02371252 Phase 4 Generic alendronate
11 A Randomized, Double-blind, Placebo-controlled Study Evaluating the Analgesic Effects of the Gastrolith, in Osteoporotic Patients Suffering From Recent Skeletal Pain Caused by Vertebral Fractures Unknown status NCT01482858 Phase 4
12 Effects of Omega-3 Fatty Acids on Bone and Frailty Unknown status NCT00634686 Phase 4
13 A Comparative Study of Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following Hemiarthroplasty in Patients With Osteoporotic Femoral Neck Fractures Unknown status NCT02148848 Phase 4 Risedronate
14 The Treatment of Osteoporosis Using a Combination of Teriparatide (Forteo) and Denosumab Unknown status NCT02130973 Phase 4 Standard Clinical Practice Regimen;Experimental Cyclic Regimen
15 Multi-centre Clinical Trial on Hormone Replacement Treatment in China Unknown status NCT01698164 Phase 4 estradiol plus MPA;Ximingting Tablet;estradiol plus progesterone
16 A Randomized, Double Blind, Single Simulation, Parallel Controlled, Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
17 The Effect of Zoledronic Acid to Bone Fusion and Bone Metabolism of Patients With Lumbar Degenerative Disease After Lumbar Interbody Fusion Unknown status NCT01310465 Phase 4 zoledronic acid;sodium chloride
18 Maintenance of Vitamin D Sufficiency With Oral Vitamin D Supplementation in Malaysian Women of Malay and Indian Ethnicity With Post Menopausal Osteoporosis Unknown status NCT02389179 Phase 4 Vitamin D3
19 Switch Risperidone to Aripiprazole in Early Stage of Pharmacotherapy of Schizophrenia Unknown status NCT00352339 Phase 4 Rispridoen and Aripiprazole;Risperidne;Abilify
20 Open Labeled, Propective, Multicentric Phase IV Study to Examine the Influence of Pharmacogenetic Markers on the Efficacy and Side Effects in Postmenopausal, Steroid Hormone Positive Breast Cancer Patients, Who Are Treated With Letrozol. Unknown status NCT01908556 Phase 4 Letrozole
21 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
22 Effect of Enteral Genistein Supplementation on Inflammatory Cytokines, Morbidity and Mortality in Patients With Sepsis Unknown status NCT02796794 Phase 4
23 A Feasibility Study to Explore the Difference in Healing Time Between Teriparatide Treatment and Standard Care on Weber B Ankle Fractures in Older People Unknown status NCT02955056 Phase 4 Forsteo
24 The Effect of Vitamin D Supplementation on Calcium Excretion in Thalassemia: a Dose Response Study Unknown status NCT01323608 Phase 4 Vitamin D3;Placebo
25 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4 prednisolone
26 Can Alendronate Suppress Aortic and Coronary Artery Calcification and Improve Bone Mineral Density in Chronic Peritoneal Dialysis Patients? Unknown status NCT00299572 Phase 4 alendronate (Fosamax)
27 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
28 Unipedicular vs. Bipedicular Kyphoplasty for the Treatment of Osteoporotic Vertebral Fractures Completed NCT01383616 Phase 4
29 Study of Curette Use for Obtaining Restoration of Vertebral Body Anatomy in Balloon Kyphoplasty Completed NCT00810043 Phase 4
30 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
31 Study to Evaluate the Clinical Performance of the VBS System for the Treatment of Osteoporotic Vertebral Fractures in a Multicenter, Randomized, Controlled Setting Completed NCT01847898 Phase 4
32 Effects of Teriparatide in Postmenopausal Women With Osteoporosis Previously Treated With Alendronate or Raloxifene Completed NCT00079924 Phase 4 teriparatide;aldrenodate;raloxifene
33 Prospective Randomized Study of Balloon Kyphoplasty and Vertebroplasty in Subacute (Older Than 6 Weeks) Osteoporotic Vertebral Fractures (STIC2) Completed NCT00749086 Phase 4
34 Efficacy of Teriparatide Treatment in Patients With New Forms of Inherited Low-Turnover Osteoporosis Completed NCT01360424 Phase 4 Teriparatide
35 Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption Completed NCT01750086 Phase 4 Teriparatide 40-mcg subcutaneous injection;Denosumab Injection;Alendronate Oral Tablet
36 Teriparatide Compared With Alendronate on Spine Bone Mineral Density in Postmenopausal Women With Osteoporosis Completed NCT02416271 Phase 4 Teriparatide;Alendronate;Placebo-Oral;Placebo-SC
37 Differential Effects of Teriparatide and Strontium Ranelate on Bone Remodeling and Formation in Postmenopausal Women With Osteoporosis Completed NCT00239629 Phase 4 Teriparatide;Strontium ranelate
38 Comparison of Raloxifene and Strontium Ranelate on Compliance and Efficacy in Women With Postmenopausal Osteoporosis Completed NCT01544894 Phase 4 Raloxifene;Strontium ranelate
39 Denosumab in Current Users of Bisphosphonates for Glucocorticoid-induced Osteoporosis: a Randomized Controlled Trial Completed NCT01465568 Phase 4 Denosumab;bisphosphonates
40 A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Phase IV Study in Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Actonel(Rosedronate) is Administered 35mg Once a Week or 5mg Completed NCT00549965 Phase 4 Risedronate Sodium
41 Bone Marker Changes In One Month Treatment With TERIPARATIDE (LY333334) Injections (rDNA Origin) in Men and Postmenopausal Women With Severe Osteoporosis Completed NCT00532545 Phase 4 Teriparatide
42 A One Year, Parallel, Placebo-controlled, Double-blind, Randomized Study to Assess the Effect of Monthly 150mg Oral Ibandronate Dosing Versus Placebo on Bone Quality and Strength at the Proximal Femur in Women With Osteoporosis Completed NCT02948881 Phase 4 ibandronate
43 A Study of Carotid Artery Intima-Media Thickness Following Exposure to Raloxifene HCl or Placebo Completed NCT00532246 Phase 4 raloxifene;Placebo
44 EVA: Evista Alendronate Comparison Completed NCT00035971 Phase 4 raloxifene HCI and alendronate Na
45 A Prospective Open-Label, Multicenter Study to Evaluate the Change in Bone Turnover Markers After Once Monthly Oral Ibandronate Therapy in Treatment Naive Postmenopausal Osteoporosis Patients Completed NCT02598934 Phase 4 Ibandronate
46 A Randomized, Open-Label, Muti-Center Study to Investigate Patient Preference on Dosing in Women With Postmenopausal Osteoporosis Treated With Once-Monthly Ibandronate and Once-Weekly Alendronate. A Six Month, Two-Sequence, and Two-Period Crossover Study Completed NCT02598440 Phase 4 Alendronate;Ibandronate
47 A Prospective, Open-Label, Multi-Center, Two-Part Study to Investigate Patient Satisfaction With Monthly Dosed Ibandronate Therapy in Women With Post-Menopausal Osteoporosis or Osteopenia Transitioned From Once-Weekly Alendronate or Risendronate Completed NCT02604836 Phase 4 Ibandronate
48 Open Label, Multi-centre, Longitudinal, Prospective, Phase IV Clinical Trial to Compare Two Image Technologies (ImaTx and DXA) Assessing the Anabolic Effects of PTH(1-84) in Postmenopausal Women With Primary Osteoporosis Completed NCT00583518 Phase 4 Parathyroid hormone (PTH)
49 Short-Term Menatetrenone Therapy Increases Gamma-Carboxylation Of Osteocalcin With A Moderate Increase Of Bone Turnover In Postmenopausal Osteoporosis: A Randomized Prospective Study Completed NCT00548509 Phase 4 Menatetrenone (Vitamin K2)
50 An Open-label, Clinical Observation Extension Study to Assess Continuing Safety and Adherence in Patients With Postmenopausal Osteoporosis Receiving Monthly Oral Bonviva Completed NCT00545090 Phase 4 ibandronate [Bonviva/Boniva]

Search NIH Clinical Center for Bone Mineral Density Quantitative Trait Locus 15

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Cholecalciferol
Fluorides
Medium chain triglycerides
MEDRONATE DISODIUM
SODIUM FLUORIDE PWDR

Genetic Tests for Bone Mineral Density Quantitative Trait Locus 15

Anatomical Context for Bone Mineral Density Quantitative Trait Locus 15

MalaCards organs/tissues related to Bone Mineral Density Quantitative Trait Locus 15:

40
Bone, Breast, Prostate, Testes, Kidney, Bone Marrow, Liver

Publications for Bone Mineral Density Quantitative Trait Locus 15

Articles related to Bone Mineral Density Quantitative Trait Locus 15:

(show top 50) (show all 30004)
# Title Authors PMID Year
1
A novel microRNA targeting HDAC5 regulates osteoblast differentiation in mice and contributes to primary osteoporosis in humans. 61 56 6
19920351 2009
2
Association of genetic variation of the RIL gene, encoding a PDZ-LIM domain protein and localized in 5q31.1, with low bone mineral density in adult Japanese women. 6
12908099 2003
3
Calcitonin receptor polymorphism is associated with a decreased fracture risk in post-menopausal women. 6
9817931 1998
4
Allelic variants of human calcitonin receptor: distribution and association with bone mass in postmenopausal Italian women. 6
9571205 1998
5
Allelic variants of human calcitonin receptor in the Japanese population. 6
9003491 1997
6
Inhibition of tanshinone IIA on renin activity protected against osteoporosis in diabetic mice. 61
32202179 2020
7
Evaluation of relationship between SPON1 gene and genetic susceptibility of postmenopausal osteoporosis. 61
32484721 2020
8
Bone marrow edema syndrome/transient osteoporosis of the hip joint and management with the utilization of hyperbaric oxygen therapy. 61
32280165 2020
9
Does osteoporosis affect the healing of subcapital humerus and distal radius fractures? 61
32425424 2020
10
Challenges and strategies in management of osteoporosis and fragility fracture care during COVID-19 pandemic. 61
32523258 2020
11
Response to Letter to the Editor: "Risk for Infections During Treatment with Denosumab for Osteoporosis: a Systematic Review and Meta-analysis". 61
32445567 2020
12
Novel approach for pathogenesis of osteoporosis in ovariectomized rats as a model of postmenopausal osteoporosis. 61
32339647 2020
13
Liquiritigenin reduces osteoclast activity in zebrafish model of glucocorticoid-induced osteoporosis. 61
32534995 2020
14
ERRATUMERRATUM for "Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis". 61
32516411 2020
15
Serum concentrations of perfluoroalkyl substances and their association with osteoporosis in a population in Jeddah, Saudi Arabia. 61
32485360 2020
16
Letter to the Editor: "Risk for Infections During Treatment With Denosumab for Osteoporosis: a Systematic Review and Meta-Analysis". 61
32445563 2020
17
Anti-osteoporotic effects of Salvia miltiorrhiza Bunge EtOH extract both in ovariectomized and naturally menopausal mouse models. 61
32311485 2020
18
Extraction, purification and anti-osteoporotic activity of a polysaccharide from Epimedium brevicornum Maxim. in vitro. 61
31751710 2020
19
Expression of Concern: "Menatetrenone (Vitamin K2) and Bone Quality in the Treatment of Postmenopausal Osteoporosis." Nutrition Reviews 2006;64(12):509-517. 61
32412060 2020
20
Establishment of the concurrent experimental model of osteoporosis combined with Alzheimer's disease in rat and the dual-effects of echinacoside and acteoside from Cistanche tubulosa. 61
32278031 2020
21
Transient Familial Factor V Leiden-Linked Hip Osteoporosis. 61
32229104 2020
22
Osteoporosis treatment gap in a prospective cohort of volunteer women. 61
32128600 2020
23
Practical guidance for the use of bisphosphonates in osteoporosis. 61
32222607 2020
24
Osteoporosis epidemiology using international cohorts. 61
32453035 2020
25
Total hip arthroplasty in patients with osteoporosis. 61
31672068 2020
26
Osteoporosis in the age of COVID-19. 61
32346775 2020
27
Cost-effectiveness of five versus ten years of alendronate treatment prior to drug holiday for women with osteoporosis. 61
32020265 2020
28
Investigation of bone matrix composition, architecture and mechanical properties reflect structure-function relationship of cortical bone in glucocorticoid induced osteoporosis. 61
32224161 2020
29
The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis. 61
32234415 2020
30
PSMC6 promotes osteoblast apoptosis through inhibiting PI3K/AKT signaling pathway activation in ovariectomy-induced osteoporosis mouse model. 61
32017075 2020
31
Automatic opportunistic osteoporosis screening using low-dose chest computed tomography scans obtained for lung cancer screening. 61
32072260 2020
32
Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis. 61
31628810 2020
33
Synthesis and biological activities of drugs for the treatment of osteoporosis. 61
32335412 2020
34
Bushenhuoxue formula promotes osteogenic differentiation of growth plate chondrocytes through β-catenin-dependent manner during osteoporosis. 61
32334373 2020
35
Abeliophyllum distichum Nakai alleviates postmenopausal osteoporosis in ovariectomized rats and prevents RANKL-induced osteoclastogenesis in vitro. 61
32268206 2020
36
Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment. 61
32020264 2020
37
Network pharmacology approach to elucidate possible action mechanisms of Sinomenii Caulis for treating osteoporosis. 61
32325182 2020
38
Non-coenzyme role of vitamin B1 in RANKL-induced osteoclastogenesis and ovariectomy induced osteoporosis. 61
32100911 2020
39
Physically Optimized Nano-Lipid Carriers Augment Raloxifene and Vitamin D Oral Bioavailability in Healthy Humans for Management of Osteoporosis. 61
32194094 2020
40
Raloxifene improves TNF-α-induced osteogenic differentiation inhibition of bone marrow mesenchymal stem cells and alleviates osteoporosis. 61
32550885 2020
41
A patient-level key performance indicator set to measure the effectiveness of fracture liaison services and guide quality improvement: a position paper of the IOF Capture the Fracture Working Group, National Osteoporosis Foundation and Fragility Fracture Network. 61
32266437 2020
42
Isoalantolactone inhibits RANKL-induced osteoclast formation via multiple signaling pathways. 61
32388216 2020
43
Bone, inflammation and chronic kidney disease. 61
32275989 2020
44
Nicotinamide mononucleotide attenuates glucocorticoid‑induced osteogenic inhibition by regulating the SIRT1/PGC‑1α signaling pathway. 61
32377728 2020
45
Dual targeting of SREBP2 and ERRα by carnosic acid suppresses RANKL-mediated osteoclastogenesis and prevents ovariectomy-induced bone loss. 61
31907393 2020
46
Validation of the self-administered comorbidity questionnaire adjusted for spondyloarthritis: results from the ASAS-COMOSPA study. 61
31665462 2020
47
Effects of anti-osteoporosis drugs against dexamethasone-induced osteoporosis-like phenotype using a zebrafish scale-regeneration model. 61
32220570 2020
48
IQ driving QI: the Asia Pacific Consortium on Osteoporosis (APCO): an innovative and collaborative initiative to improve osteoporosis care in the Asia Pacific. 61
32561953 2020
49
MANAGEMENT OF ENDOCRINE DISEASE: Male osteoporosis: diagnosis and management. Should the treatment and target be the same as for female osteoporosis? 61
32544873 2020
50
3'-UTR Polymorphisms of Vitamin B-Related Genes Are Associated with Osteoporosis and Osteoporotic Vertebral Compression Fractures (OVCFs) in Postmenopausal Women. 61
32498429 2020

Variations for Bone Mineral Density Quantitative Trait Locus 15

ClinVar genetic disease variations for Bone Mineral Density Quantitative Trait Locus 15:

6 ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MIR2861 NR_036055.1(MIR2861):n.33C>GSNV association 106 rs794728003 9:130548229-130548229 9:127785950-127785950
2 PDLIM4 RIL, -3333T-CSNV risk factor 6348
3 CALCR NM_001742.4(CALCR):c.1340T>C (p.Leu447Pro)SNV risk factor 17636 rs1801197 7:93055753-93055753 7:93426441-93426441
4 TRPV6 NM_018646.6(TRPV6):c.1978G>C (p.Gly660Arg)SNV Likely pathogenic 818220 7:142570162-142570162 7:142872409-142872409

Expression for Bone Mineral Density Quantitative Trait Locus 15

Search GEO for disease gene expression data for Bone Mineral Density Quantitative Trait Locus 15.

Pathways for Bone Mineral Density Quantitative Trait Locus 15

GO Terms for Bone Mineral Density Quantitative Trait Locus 15

Sources for Bone Mineral Density Quantitative Trait Locus 15

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....